Alloy Therapeutics, Inc.’s Post

Discover the Future of AI Drug Discovery with Syntekabio at BIO! 📍 Visit us in Booth #5435 at the San Diego Convention Center, June 3-6, 2024. Explore how Syntekabio de-risks and streamlines drug discovery with our robust #AI-driven platforms. Leveraging our powerful infrastructure, we rapidly discover and deliver both small molecules and biologics, including antibodies and neoantigens. We experimentally validate our work in cooperation with our global CRO network and can deliver a package that’s ready for the clinic. 🧬 Learn more about our innovative solutions: 🔬Syntekabio In Silico Biologics: includes Neo-ARS, our cutting-edge AI platform for personalized or universal #neoantigen prediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. 🚀 STB LaunchPad: proprietary disease-agnostic technology platform that can generate hits, leads, and ultimately drug candidates against multiple targets. 🌟 We look forward to meeting you to tell you more about how our platforms can generate new chemical entities and preclinical assets, simplifying and accelerating the path from discovery to development. 🤝 🗓️ Schedule a meeting via the partnering system at https://lnkd.in/dNYY4ts7 or drop by Booth 5435 to discuss how our innovative solutions can enhance your drug discovery efforts. #BIO2024 #drugdiscovery #BIOInternational #BIOConvention

Every week, our interactions with expert drug developers keep us plugged into the pulse of innovation. These conversations fuel our MicroSummits and help us bring the most relevant and impactful discussions to the forefront. This week we had several conversations with senior Biotech leaders in the complex Biologics space, with a particular focus on Antibody Drug Conjugates: 🦠 Enhanced Targeting Precision in ADCs - Recent advancements in ADC technology have led to improved targeting capabilities, allowing for more precise delivery of the therapeutic payload to cancer cells. This refinement in targeting reduces off-target effects and enhances the efficacy of the treatment, making ADCs a more precise tool in the fight against cancer. 🧬 Focus on Payloads in ADC Development - A significant trend in the ADC space is the focus on enhancing the payload, the component that delivers the therapeutic effect. Recent collaborations, such as those between Merck and Daiichi Sankyo, are a testament to this, with many companies now prioritizing advancements in payload technology for better efficacy and safety. 🌡️ Increased Safety in Newer ADCs - Modern ADCs are showing much higher Maximum Tolerated Doses (MTD) in clinical studies compared to earlier drug classes. This indicates a substantial improvement in the safety profile of ADCs, making them more viable for treating a wider range of conditions without severe toxicity concerns. Are you enthusiastic about meaningful discussions with your peers in drug developers? Get in touch to find out about speaker opportunities or join one of our upcoming sessions. Always free for drug developers. #adcs #Biotech #BiotechEvents #MicroSummits

📣PRELIMINARY AGENDA JUST RELEASED! The PEGS Boston Summit brings together leading experts at the forefront of #biologics innovation, providing insights into the latest technologies, research, and advancements in drug development, protein and antibody engineering, #immunotherapy, #immunogenicity, expression platforms, multispecific #antibodies , #machinelearning and AI in biologics, and more. Click below for a sneak peek at the programs and list of confirmed speakers. https://lnkd.in/gbKaax7E #PEGSummit #pegseurope #proteinengineering #antibodytherapeutics

We’re looking at the drug development pipeline - past, present, and future. For some key insights from The Antibody Society’s “Antibodies to Watch in 2024” survey, just click the link below to get our view on what the industry is celebrating today . . . and what it just might be celebrating tomorrow. https://hubs.li/Q02NQMQV0 #antibodies #antibodydiscovery

🌐 Exciting Update from PEGS Europe 2023! 🌐 I am thrilled to share that our very own Megan Thomas from DDW recently had the opportunity to attend the prestigious PEGS Europe 2023 in Lisbon, Portugal. 🌍 Presenting her insights while also acknowledging notable contributions from our industry peers. 🚀 Special Product Introductions & Launches: - Molecular Devices and Azenta Life Sciences have introduced groundbreaking products, paving the way for innovation in the biologics landscape. 🌟 Poster Spotlights by Industry Leaders: - Dive into insightful poster spotlights by Bio-Rad Laboratories, Charles River Laboratories, Promega Corporation , Absolute Antibody. Their contributions add depth to the conversations around cutting-edge research and development. 🔍 Special Meet the Exhibitor Presentations: - Gail Calvert from Sartorius - Telesis Bio - Sphere Fluidics Limited - Revvity - Malvern Panalytical Pharmaceuticals These presentations provided a unique perspective on the latest advancements, challenges, and opportunities in the biologics space. Stay tuned for a wealth of knowledge from these industry leaders. Click the link to read the full review. #BiologicsTechnology #Innovation #IndustryLeaders #PEGSHighlights #drugdiscovery #drugdevelopment #antibodies #antibodydiscovery #workflowautomation #biologics #events #pegseurope2023 #proteinengineering Drug Discovery World https://lnkd.in/gwqCg54F

Thank you to everyone who participated in our recent poll on the potential impact of existing and emerging antibody therapeutic modalities. The results showed the strongest interest in monoclonal antibodies, with 39% of votes, closely followed by both antibody-drug conjugates and bi/multispecific antibodies at 26% each. The Wheeler Bio, Inc. team is commited to supporting the advancement of antibody therapeutics by maintaining an intense focus on ameliorating translational challenges as these modalities advance to clinic. By leveraging our turnkey antibody platform, Portable CMC®, we offer comprehensive services for antibody development and CGMP clinical manufacturing that streamline CMC development. This platform is not only designed to accelerate the transition from discovery to IND, but it also ensures scalability and high yields which are crucial for the cost-effective development of antibody-based treatments. Learn how Wheeler helps antibody developers advance their programs more quickly, flexibly, and cost-effectively: https://lnkd.in/e_PTWteS #pharmaindustry #biotech #antibodies #clinicaltrials

Our CEO Maria Lisa Knudsen, PhD sat down for an interview with Scrip to talk about AAX Biotech and our exciting technologies, summarized nicely in this article “Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies”:   “Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.   … AAX can boast not one but two technologies which both aim to produce more effective antibody-based medicines. The first is Opti-mAb which improves the stability and production of single- chain variable fragments (scFv), an antibody format used in CAR-T and bispecifics.   AAX's second technology is Seqitope, which the company says is an innovative method for antibody epitope mapping which yields high-resolution results while also being high throughput.”   Full article: https://lnkd.in/dw9kGYTd   Citeline Commercial #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment

 Major Partnerships in AI-focused biotech 🔬 Absci and AstraZeneca: A $247 million deal was announced in December 2023 to develop AI-designed anticancer antibodies. 🔬 BigHat Biosciences and AbbVie: A collaboration worth over $200 million to leverage AI for antibody development. 🔬 BigHat Biosciences and Almirall: A $610 million deal to create AI-designed therapeutics for dermatological diseases. 🔬 Sanofi and BioMap: A partnership potentially worth more than $1 billion to develop AI models for biological design. 🔬 Xaira Therapeutics, Co-founded by David Baker, is an AI-focused biotech that launched with over $1 billion in funding. It aims to use generative AI tools like diffusion models to design next-generation biologics. 🤝 These partnerships and innovations are not just significant; they are game-changers. They underscore the growing impact of AI in biotech, paving the way for faster and more efficient development of therapeutic antibodies. The integration of AI and biologics expertise is poised to revolutionize the industry, offering new hope for the treatment of various diseases. #artificalintelligence

Choose wisely! Decisions made early in drug discovery are linked to later success or failure. Find comprehensive tools for target validation, mAb production and purification, screening, lead optimization, preclinical evaluation, and more. #drugdevelopment #mAbs #discovery #targetidentification

Are you ready to turbocharge your antibody discovery process? 🧬 Don’t miss out on our upcoming presentation, “Turbocharge your antibody discovery with AbTheneum,” happening on 23rd September 2024, from 15:00 - 15:30 at the Antibody Therapeutics Xchange - San Francisco 2024! 🔎 Discover how Single Cell Technology Inc.'s ground-breaking AbTheneum platform—based on single B cell technology—can transform antibody discovery efforts with unmatched speed and versatility. The platform generates thousands of antibody sequences in just three weeks, integrating multiple assays during the discovery phase to ensure the identification of differentiated antibodies. With over eight years of experience and partnerships with leading pharma companies, Single Cell Technology Inc. consistently delivers exceptional results. SurfScreen, Single Cell Technologies' innovative module designed to tackle challenging membrane targets will also be unveiled! 🧫 🗣️ Leading the presentation will be Allison Schulkins, Chief Operating Officer, Single Cell Technology Inc. Allison has been pivotal in turning the AbTheneum platform from an idea into a powerful tool that’s accelerating therapeutic programs across the industry. 🔗 Register now to secure your spot and learn how AbTheneum can accelerate your pipeline and advance your therapeutic programs efficiently. 👉 https://lnkd.in/efZJrzDU 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyDiscovery #BiotechInnovation #AbTheneum #SingleCellTechnology #AntibodyTherapeutics #LifeSciences #Biopharma #SanFrancisco2024 #AntibodyEngineering #BiotechBreakthroughs #PharmaInnovation #DrugDiscovery #LifeScienceResearch #TherapeuticDevelopment #Biotechnology #CellTherapy #PrecisionMedicine #BiopharmaExcellence #InnovativeScience #BiotechLeadership #MedicalResearch #NextGenTherapeutics #PharmaScience #AntibodyXchange #BiotechRoundtable #ScientificResearch #IndustryExpert #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass